MEDEXIS is a biotechnology company that identifies, develops and commercializes new life science technologies. A special focus of the company is to foster products to detect or treat human disease.

Founded in 2002, Medexis is a proud member of the Gerolymatos International Group of Companies (GI) based in Athens, Greece. GI is a privately held health & beauty company with strong international presence (Europe, North America, China) and an impressive track record in the development and sale of a wide range of health care products.

MEDEXIS has a growing portfolio of therapeutic and diagnostic projects that address unmet needs in oncology. The company has recently developed and approved an In Vitro Diagnostic (IVD), PCR-based kit for the detection of Circulating Tumor Cells in biological samples (CK-19 Quantification Kit). Several drug candidates showing potent in vitro and in vivo anti-cancer activity are currently being pursued in pre-clinical trials.

MEDEXIS works closely with individual scientists, corporations and academic institutions throughout Europe and the United States. The company is based in Athens (Kryoneri), Greece.